About Us
Advancing innovative solutions for severe rare diseases
Our mission
Around the world, patients with severe, progressive rare diseases continue to face limited therapeutic options and significant unmet medical need, creating meaningful opportunity for differentiated innovation.
At SCYNEXIS, we are focused on advancing a portfolio of highly differentiated, clinical‑stage assets targeting the underlying biology of severe rare diseases. Our programs are designed around the needs of patients facing limited options, with a focus on delivering clinically meaningful benefit.
Guided by deep scientific expertise and disciplined drug development execution, we strive to improve outcomes for patients who urgently need better solutions
Our work is focused on advancing innovative solutions for severe rare diseases
-
ADPKD: A serious genetic kidney disease with significant unmet need
Autosomal dominant polycystic kidney disease (ADPKD) is a progressive, inherited condition in which fluid‑filled cysts develop and enlarge in the kidneys over time. As the disease advances, kidney function can decline, and many people ultimately face kidney failure that may require dialysis or transplant.
Learn More
Direct activation of AMPK, a key regulator of cellular metabolism, is emerging as a promising strategy for treating ADPKD by addressing many of the disease’s underlying metabolic abnormalities that drive cyst growth -
Life-threatening Infections
Serious, invasive and often deadly fungal infections treated in the hospital setting are increasingly drug resistant. Our first-in-class antifungal platform can give patients and healthcare professionals innovative new weapons to deploy against these dangerous diseases.
LEARN MORE
Success backed by
strong leadership
Our leaders have deep experience in drug development, impressive business acumen and an unwavering commitment to excellence.
Learn MoreMake a difference.
Join our team.
We have an unrelenting commitment to making a difference in the lives of patients.
Learn More